Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

News
Video

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Related Videos
Jean L. Koff, MD, MS
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video 9 - "Additional Second-Line Treatments for HCC"
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Related Content
Gulrayz Ahmed, MD, the Medical College of Wisconsin

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024
Article
Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023
Podcast
Michael Wang, MD

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024
Article
Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022
Podcast
stock.adobe.com

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024
Article
CTL019 in MCL| Image Credit: © Dr_Microbe - stock.adobe.com

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024
Article